4 completed, 1 terminated. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Terminated 1 |
Follow Taris Biomedical LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200, Nivolumab Injection [Opdivo] - Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A | Phase 1 | Terminated | Taris Biomedical LLC | 13 | 2019-01-02 | 2024-08-27 |
| Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury Trospium-Releasing Intravesical System (TAR-302-5018) - Neurogenic Detrusor Overactivity | Phase 1 | Completed | Taris Biomedical LLC | 7 | 2017-04-24 | 2020-01-13 |
| Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder Trospium-Releasing Intravesical System (TAR-302-5018) - Idiopathic Overactive Bladder With Urinary Incontinence | Phase 1 | Completed | Taris Biomedical LLC | 43 | 2017-04-04 | 2020-01-13 |
| Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 - Urinary Bladder Cancer | Phase 1 | Completed | Taris Biomedical LLC | 23 | 2016-05-31 | 2023-09-18 |
| Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 - Urinary Bladder Cancer | Phase 1 | Completed | Taris Biomedical LLC | 12 | 2016-01-01 | 2020-03-10 |
Urinary Bladder Neoplasms (3) · Carcinoma, Transitional Cell (1)
Nivolumab (1)
United States (4) · Netherlands (2)
Christopher Cutie, MD (2) · Johannes Witjes, MD (1) · Michael Kennelly, MD (1) · Siamak Daneshmand, MD (1)
2016 (1)